News - Pharmaceuticals
Sigma withdraws API merger proposal paving way for Wesfarmers to take control

Pharma News: Sigma Healthcare announced that it will not proceed with its current proposal to merge with Australian Pharmaceutical Industries Limited (API).
In September, Sigma had put forth a bid to merge with API, which at $1.57 per share was higher than Wesfarmers’ offer of $1.55, who owns Coles, Bunnings and Kmart.
Whilst the Board of Sigma remains of the view that Sigma’s merger proposal with API was a very strong proposal for all stakeholders, particularly given the $45 million of operational synergies per annum that it believes would likely have been created for API and Sigma shareholders, the Sigma Board put an end to the process.
Sigma Chairman, Ray Gunston, commented “Sigma believed it made economic, commercial and strategic sense to pursue the merger proposal between Sigma and API on the terms we presented. However, after further assessment, and in the context of the competitive bid process with its changing transaction and economic considerations, Sigma has made the decision not to proceed with this current proposal.
“Sigma remains confident of our growth prospects without a merger with API and the Board and management have continued to focus on longer term growth in our core operations. The Sigma team will keep on working to finalise the completion of our infrastructure upgrade, including our ERP project, and to remain focused on leveraging our infrastructure to create greater shareholder value,” he said.
If Wesfarmers is successful, it sees opportunities to invest to strengthen the competitive position of API, improving supply chain capabilities and enhancing the online experience for customers. API would also form the basis of a new healthcare division of Wesfarmers with an opportunity to invest in the growing health, wellbeing and beauty sector.
“Notwithstanding some short-term challenges in the current year, we believe the Sigma business base provides a positive longer-term outlook. Sigma’s investments in its operations, and its strong balance sheet and future cash generation, underpin the future strategic directions that will be shaped under the leadership of our new CEO Vikesh Ramsunder from February 2022,” Gunston concluded. Ramsunder will take the helm in February from long-serving boss Mark Hooper.
News - MedTech & Diagnostics
Roche unlocks new horizons for genomic research in Asia Pacific
Roche is advancing its next-generation sequencing (NGS) ambitions in Asia Pacific following the global launch of AXELIOS 1 in June […]
MoreNews - Pharmaceuticals
‘Unexpected and surprising’: Novartis Lp(a) setback raises tough questions for Amgen and Lilly
The failure of Novartis’ lipoprotein(a) [Lp(a)] therapy to translate substantial biomarker reductions into meaningful cardiovascular benefits has been met with […]
MoreNews - MedTech & Diagnostics
More public hospitals turn to same-day hip and knee surgery, but key blind spots persist
Same-day hip and knee replacements to ease surgical waiting lists are being trialled at The Royal Adelaide Hospital (RAH), but […]
MoreNews - Pharmaceuticals
TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning
The Therapeutic Goods Administration (TGA) approval of Novo Nordisk’s oral GLP-1 receptor agonist Wegovy (semaglutide) is introducing a new dimension to […]
More